Moderna prices COVID-19 vaccine at $32-$37 per dose for smaller volume deals




  • In US
  • 2020-08-05 12:54:35Z
  • By Reuters
FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts
FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts  

By Ankur Banerjee and Carl O'Donnell

(Reuters) - Moderna Inc <MRNA.O> said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc's <PFE.N> vaccine candidate.

As the race to develop COVID-19 vaccines reach a decisive stage, with several candidates being tested in pivotal late-stage studies, pricing has come under increasing scrutiny.

"We will be responsible on price well below (its) value during the pandemic," Chief Executive Officer Stéphane Bancel said on a conference call, adding that larger volume agreements for its vaccine will be priced lower.

Last month, the U.S. government struck a deal for an experiment vaccine being developed by Pfizer and partner BioNTech SE <22UAy.F> that secures enough vaccine to inoculate 50 million Americans for about $40 a person. Moderna's two-dose vaccine regimen would cost between $64 and $74 per person.

Moderna, which has no drugs on the market, has received nearly $1 billion from the U.S. government under a plan to speed up vaccine development. It has not struck a supply agreement with the United States.

The company said on Wednesday it was in talks with several countries for supply agreements for its vaccine, adding that it had already received about $400 million in deposits for eventual supply.

Moderna said enrolment for its late-stage vaccine study that aims to include 30,000 people is on track to be completed in September.

The company's vaccine candidate is one of the few that have already advanced to the final stage of testing. Effective vaccines are seen as essential to halting a pandemic that has claimed more than 700,000 lives worldwide.

Moderna said last month it plans to price its coronavirus vaccine in a way that ensures broad access and that it did not intend to conduct late-stage trials of the vaccine outside the United States.

Moderna shares fell 5% in early trading on Wednesday.


(Reporting by Ankur Banerjee in Bengaluru and Carl O'Donnell in New York ; Editing by Saumyadeb Chakrabarty and Bill Berkrot)

COMMENTS

More Related News

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
  • US
  • 2020-09-25 18:56:18Z

A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc , could simplify distribution of the vaccine. The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.

J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine
J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine
  • US
  • 2020-09-25 14:05:14Z

Michigan-based GRAM will manufacture the healthcare conglomerate's SARS-CoV-2 vaccine candidate, which is being developed with part funding from the U.S. government, and provide finished vials. Earlier in the week, J&J launched a late-stage trial of its experimental single-shot COVID-19 vaccine and said its expects results of the trial by year end or early next year. J&J, which is readying its supply chain to start distribution as soon as it gets FDA's approval, expects to manufacture as many as 1 billion doses in 2021.

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers. "BioNTech's vaccine candidate is not part of this study," a spokeswoman said. Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying.

Chinese company says coronavirus vaccine ready by early 2021
Chinese company says coronavirus vaccine ready by early 2021

A Chinese pharmaceutical company said Thursday the coronavirus vaccine it is developing should be ready by early 2021 for distribution worldwide, including the United States. Yin Weidong, the CEO of SinoVac, vowed to apply to the U.S. Food and Drug Administration to sell CoronaVac in the United States if it passes its third and final round of testing in humans. Yin said he personally has been given the experimental vaccine.

China
China's Sinovac eyes coronavirus vaccine distribution in South America
  • US
  • 2020-09-24 09:53:47Z

China's Sinovac Biotech hopes to supply its experimental coronavirus vaccine to more South American countries by outsourcing some manufacturing procedures to a partner in Brazil, its chief executive said on Thursday. Global vaccine makers, such as Sinovac and AstraZeneca, have partnered with Brazil to conduct late-stage trials of their vaccine candidates in South America's largest nation, battling with the third highest tally of infections worldwide.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US